Takeda invests $4.66 billion in oncology market with Ariad deal
Bloomberg Takeda Pharmaceutical Co. will expand its footprint in the US oncology market with the $4.66 billion purchase of Ariad Pharmaceuticals Inc., adding one potential blockbuster in lung cancer and another already on-the-market therapy. Takeda will pay $24 a share for Ariad, the companies said in a statement, 75 percent more than its Friday close of $13.74. The deal ...
Read More »